339 related articles for article (PubMed ID: 21922382)
1. Hepatocellular carcinoma and liver transplantation: clinical perspective on molecular targeted strategies.
Matsuda Y; Ichida T; Fukumoto M
Med Mol Morphol; 2011 Sep; 44(3):117-24. PubMed ID: 21922382
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation.
Gomez-Martin C; Bustamante J; Castroagudin JF; Salcedo M; Garralda E; Testillano M; Herrero I; Matilla A; Sangro B
Liver Transpl; 2012 Jan; 18(1):45-52. PubMed ID: 21932373
[TBL] [Abstract][Full Text] [Related]
3. Radiologic complete response with sirolimus and sorafenib in a hepatocellular carcinoma patient who relapsed after orthotopic liver transplantation.
Kim R; Aucejo F
J Gastrointest Cancer; 2011 Mar; 42(1):50-3. PubMed ID: 20714941
[TBL] [Abstract][Full Text] [Related]
4. Sirolimus plus sorafenib in treating HCC recurrence after liver transplantation: a case report.
Wang Y; Speeg KV; Washburn WK; Halff G
World J Gastroenterol; 2010 Nov; 16(43):5518-22. PubMed ID: 21086573
[TBL] [Abstract][Full Text] [Related]
5. Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo.
Newell P; Toffanin S; Villanueva A; Chiang DY; Minguez B; Cabellos L; Savic R; Hoshida Y; Lim KH; Melgar-Lesmes P; Yea S; Peix J; Deniz K; Fiel MI; Thung S; Alsinet C; Tovar V; Mazzaferro V; Bruix J; Roayaie S; Schwartz M; Friedman SL; Llovet JM
J Hepatol; 2009 Oct; 51(4):725-33. PubMed ID: 19665249
[TBL] [Abstract][Full Text] [Related]
6. Sorafenib therapy in patients with hepatocellular carcinoma before liver transplantation.
Rowe IA
Hepatology; 2010 Sep; 52(3):1171-2. PubMed ID: 20812364
[No Abstract] [Full Text] [Related]
7. Adjuvant therapy after curative treatment for hepatocellular carcinoma.
Kudo M
Oncology; 2011; 81 Suppl 1():50-5. PubMed ID: 22212936
[TBL] [Abstract][Full Text] [Related]
8. Safe use of sorafenib in a patient undergoing salvage liver transplantation for recurrent hepatocellular carcinoma after hepatic resection.
Kim R; Menon N; Aucejo F
Med Oncol; 2011 Dec; 28(4):1044-7. PubMed ID: 20635167
[TBL] [Abstract][Full Text] [Related]
9. Hepatocellular carcinoma cases with high levels of c-Raf-1 expression may benefit from postoperative adjuvant sorafenib after hepatic resection even with high risk of recurrence.
Lei J; Zhong J; Hao J; Liu Z; Zhang P; Wu L; Yan L; Zhu J; Zeng Y; Li B; Wen T; Wang W
Oncotarget; 2016 Jul; 7(27):42598-42607. PubMed ID: 26981887
[TBL] [Abstract][Full Text] [Related]
10. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
Cui SX; Shi WN; Song ZY; Wang SQ; Yu XF; Gao ZH; Qu XJ
Oncotarget; 2016 Jun; 7(24):36767-36782. PubMed ID: 27167344
[TBL] [Abstract][Full Text] [Related]
11. PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation.
Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Evers BM
J Surg Res; 2012 Aug; 176(2):542-8. PubMed ID: 22261591
[TBL] [Abstract][Full Text] [Related]
12. PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways.
Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Koch A; Evers BM
Anticancer Res; 2010 Dec; 30(12):4951-8. PubMed ID: 21187475
[TBL] [Abstract][Full Text] [Related]
13. Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3.
Gu FM; Li QL; Gao Q; Jiang JH; Huang XY; Pan JF; Fan J; Zhou J
World J Gastroenterol; 2011 Sep; 17(34):3922-32. PubMed ID: 22025881
[TBL] [Abstract][Full Text] [Related]
14. Selection of patients with hepatocellular carcinoma for sorafenib.
Abou-Alfa GK
J Natl Compr Canc Netw; 2009 Apr; 7(4):397-403. PubMed ID: 19406040
[TBL] [Abstract][Full Text] [Related]
15. What is the indication for sorafenib in hepatocellular carcinoma? A clinical challenge.
Kim R; Byrne MT; Tan A; Aucejo F
Oncology (Williston Park); 2011 Mar; 25(3):283-91, 295. PubMed ID: 21548473
[TBL] [Abstract][Full Text] [Related]
16. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
Singh AR; Joshi S; Burgoyne AM; Sicklick JK; Ikeda S; Kono Y; Garlich JR; Morales GA; Durden DL
Mol Cancer Ther; 2016 Nov; 15(11):2553-2562. PubMed ID: 27496136
[TBL] [Abstract][Full Text] [Related]
17. Hepatocellular carcinoma: sorafenib before liver transplantation?
Braillon A
Hepatology; 2010 Jun; 51(6):2232-3. PubMed ID: 20041410
[No Abstract] [Full Text] [Related]
18. [New possibilities of targeted therapy in the treatment of hepatocellular carcinoma with the help of molecular biology].
Hagymási K; Tulassay Z
Orv Hetil; 2010 Oct; 151(43):1763-8. PubMed ID: 20940115
[TBL] [Abstract][Full Text] [Related]
19. Advanced hepatocellular carcinoma. Review of targeted molecular drugs.
Alves RC; Alves D; Guz B; Matos C; Viana M; Harriz M; Terrabuio D; Kondo M; Gampel O; Polletti P
Ann Hepatol; 2011; 10(1):21-7. PubMed ID: 21301005
[TBL] [Abstract][Full Text] [Related]
20. mTOR inhibitor therapy: Does it prevent HCC recurrence after liver transplantation?
Duvoux C; Toso C
Transplant Rev (Orlando); 2015 Jul; 29(3):168-74. PubMed ID: 26071984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]